This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Opexa Therapeutics To Attend The American Academy Of Neurology Annual Meeting

Stocks in this article: OPXA

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced its participation at the American Academy of Neurology (AAN) 2014 Annual Meeting taking place from April 26 to May 3, 2014 in Philadelphia. The AAN Annual Meeting is the world’s largest gathering of neurologists, featuring breakthrough scientific research.

Opexa is sponsoring a booth at the AAN at which the leadership team will be present to discuss Tcelna, its lead therapy, which is currently in development for the treatment of Secondary Progressive Multiple Sclerosis (SPMS). Presentations and discussions on the Abili-T clinical trial, mechanism of action of Tcelna and key points of differentiation will be discussed.

Opexa is also planning to hold a meeting of Abili-T clinical trial investigators to review the status of the ongoing Phase IIb Abili-T trial in SPMS. This is a planned meeting and will include neurologists and study coordinators from several of the clinical sites.

Additionally, Opexa is hosting a reception for investors and analysts to discuss SPMS, and how a targeted, personalized therapy may be effective in addressing this unmet medical need. Two key opinion leaders, Professor Hans-Peter Hartung and Dr. Ed Fox, will provide an overview of the status of SPMS and the potential of Opexa’s T-cell immunotherapy in treating this population of MS patients.

Opexa is currently conducting the Abili-T trial, a Phase IIb study of Tcelna in SPMS patients. The trial is expected to enroll 180 patients at approximately 35 leading clinical sites in the U.S. and Canada, with each patient receiving two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months.

Opexa expects the trial to be fully enrolled in the second quarter of 2014, with top-line data expected in mid-2016. At a recently held meeting, the independent Data and Safety Monitoring Board (DSMB) overseeing Opexa’s Abili-T trial recommended the trial continue as planned based on the committee’s review of safety data from the trial. The DSMB met on April 9, 2014 and found no significant safety concerns for the trial to date. Opexa has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Tcelna in SPMS.

1 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs